Navigation Links
Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations
Date:1/27/2011

r share consists of GAAP shares used to compute diluted net income per share adjusted for any inclusions made in conjunction with dilutive impact of Thoratec’s convertible debt instruments and any exclusions made in conjunction with the application of the two-class method for calculating net income per share.

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense.

Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, amortization of purchased intangibles, and HeartWare transaction costs.

Non-GAAP other income and expense consists of GAAP other income and expenses excluding expenses related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt and unrealized gains on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP tax expense consists of the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec’s operations to exclude amortization of intangibles.  These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec’s recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors’ ability to review Thoratec’s business from the s
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com announces ... its catalogue: Russia Sinuscopes Market ... Russia Sinuscopes Market Outlook to 2020 ... Sinuscopes Market Outlook to 2020", provides key market data ... in millions of US dollars, volume (in units) and ...
(Date:8/18/2014)... 2014  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... Tomasello as its Chief Commercial Officer.  Ms. Cline ... of the Americas, Hematology and Oncology, for the Celgene ... Prior to joining Celgene, Ms. Cline Tomasello was the ... Genentech, where she was responsible for over $1.7 billion ...
(Date:8/18/2014)... Nev., Aug. 18, 2014 PDL BioPharma, Inc. (PDL) ... for the second quarter and six months ended June 30, ... quarter of 2014 increased approximately 10 percent to $162.8 ... 2013. Revenues for the second quarter of 2014 include ... al. patents, net royalty payments from Depomed, the change ...
Breaking Medicine Technology:Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4Pharmacyclics Appoints Chief Commercial Officer 2Pharmacyclics Appoints Chief Commercial Officer 3Pharmacyclics Appoints Chief Commercial Officer 4PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 2PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 3PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 4PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 5PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 6PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 7PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 8PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 9PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 10PDL BioPharma Announces Second Quarter 2014 and Year to Date Financial Results 11
... 13 Octapharma USA ... therapy development specifically for von Willebrand Disease (VWD), is now ... Food and Drug Administration (FDA) has approved wilate® ... in patients with severe VWD as well as in patients ...
... May 13 Stereotaxis, (Nasdaq: STXS ... with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, ... the scientific program of the 31st Annual Heart Rhythm ... presentations and eight posters will underscore the broad clinical ...
Cached Medicine Technology:Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 2New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 3New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 5New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 6
(Date:8/20/2014)... BuyCheapTicketsToEvents.com is always ready to please ... to many events. Cheap NHL hockey tickets are in the ... Hockey fans are enthusiastic about their sport, and they seize ... is the time to acquire 2014 NHL preseason tickets for ... will be a great deal of action and excitement, and ...
(Date:8/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sodium Chloride IV . , The ... Sodium Chloride IV 0.9%, USP 1000 mL, by Baxter International ... particulate matter. Sodium Chloride Injection, USP is used as a ... in hemodialysis procedures. , The reason for the ...
(Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
(Date:8/19/2014)... 20, 2014 The elegant bamboo floorings ... upgrade their houses in an environmentally conscious way with ... solid materials and have an aluminum oxide finish to ... suited for high-traffic areas. , Recently, the company has ... bamboo floorings . These fresh items are specially made ...
(Date:8/19/2014)... 20, 2014 Crosley Law Firm, PC has ... amputation against Lone Star Bakery for an undisclosed amount. The ... March and May of 2011, respectively. The injuries were caused ... in severe injury to the left hand of each man. ... Star Bakery was short-staffed, having lost 200 of its, 500 ...
Breaking Medicine News(10 mins):Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:BambooIndustry.com Announces Up To 30% Discount On Its New Click Strand Woven Bamboo Floorings 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2
... pediatric research institution , ... Washington, DC (Vocus) November ... Research Institute , dedicated new research facilities today, increasing the space ... than 100,000 square feet. , , , , ,Elected officials and ...
... MedNotes offers personalized medication profiles, drug interaction and warning ... , NEW YORK, Nov. 24 ... medication and related health issues, today announced the launch ... way consumers can monitor and manage their own medications, ...
... For over a decade Ochsner Health System,has enjoyed a ... improved patient care, cost savings and increased revenues for,Ochsner,s ... New Orleans have,seen more than their share of tragedy. ... left the greater New Orleans hospital infrastructure,badly damaged. ...
... With the bWell-informed Health Plan Forecaster, Medicare shoppers can ... , NEW YORK, Nov. ... first day of the holiday shopping rush. For seniors ... options, there,s no better time to "shop" for coverage ...
... Nov. 24 In preparation for its January 1,2009 ... Francisco,s highly regarded Institute on Aging (IOA). , ... nonprofit, membership-based, "aging-in-place",program designed to help older adults and ... apartments, and neighborhoods as long as they wish or ...
... 75th Annual Stockholders Meeting of Florida’s Natural Growers ... on Monday, the 17th of November. The theme ... Value,” was appropriate since the Cooperative reported one ... despite an extremely challenging economic environment. In fact, ...
Cached Medicine News:Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 2Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 4Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 5Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:bWell-informed(TM) Adds Medicare Plan Tools for 2008 Open Enrollment Season 2Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 3
... Cruise Control is ... STAAR as a filter ... and aspiration tubing that ... the safety and efficiency ...
... The robust, compact Sleepscan Traveler provides the ... can acquire PSG data in the home, ... laboratory. Traveler sleep studies utilize the same ... in-lab studies. Sleepscan Traveler studies take full ...
... Pioneer in Digital EEG ,The company ... system presents the latest addition to ... VISION. This innovative system incorporates the ... and information management to offer you ...
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
Medicine Products: